Individualized Systemic Treatment of Lung Cancer

The systemic treatment of lung cancer has revolutionized. New targeted treatment options have driven us to consider more specific subpopulations of lung cancer. For example , epidermal growth factor receptor (EGFR) inhibitors emerged as more effective in EGFR mutant patients. Crizotinib arose as a potent alternative in patients with ALK translocation. Histopathological subtypes and other predictive markers may also affect the treatment choice due to differences in the pharmacokinetics, pharmacodynamics, and therapeutic targets. As a result, lung cancer treatment has moved from a broad empirical viewpoint to a more personalized approach. In the near future, new targeted agents are likely to provide more specialized treatment options for patient.